Tumor News and Research

RSS

Findings reveal potential drug targets for small cell lung cancer

Cancer cells undergo extensive genetic alterations as they grow and spread through the body. Some of these mutations, known as "drivers," help spur cells to grow out of control, while others ("passengers") are merely along for the ride.

17 Mar 2014

Findings reveal that miR-34 genes are bona fide tumor suppressors

Cornell University researchers report they have discovered direct genetic evidence that a family of genes, called MicroRNA-34 (miR-34), are bona fide tumor suppressors.

17 Mar 2014

Longer looks: The 'making of Obamacare;' unlocking an autistic son's secrets; antibiotics and the obesity epidemic

If you walk into a farm-supply store today, you're likely to find a bag of antibiotic powder that claims to boost the growth of poultry and livestock. That's because decades of agricultural research has shown that antibiotics seem to flip a switch in young animals' bodies, helping them pack on pounds. Manufacturers brag about the miraculous effects of feeding antibiotics to chicks and nursing calves. Dusty agricultural journals attest to the ways in which the drugs can act like a kind of superfood to produce cheap meat. But what if that meat is us? (Pagan Kennedy, 3/8).

14 Mar 2014

Researcher discover new chemical class that attacks two key cancer cell building block targets

Imagine cutting down the growth of cancer cells at their earliest stages to halt tumor growth. Research conducted by leading cancer metabolism researchers at Stony Brook University, Paul M. Bingham, PhD, and Zuzana Zachar, PhD, is showing promise in this approach with their clinical investigation of a new class of compounds that disrupt cancer cell mitochondrial metabolism.

14 Mar 2014

MD Anderson collaborates with MedImmune to develop therapies that unleash patients' immune systems to attack cancers

The University of Texas MD Anderson Cancer Center and MedImmune, the global biologics research and development arm of AstraZeneca, will collaborate through MD Anderson's Moon Shots Program to develop therapies that unleash patients' immune systems to attack their cancers.

14 Mar 2014

Physician-scientists present pancreatic cancer surgery findings at SSO Cancer Symposium

Despite the benefits of surgery for early stage pancreatic cancer, it remains under-utilized for patients with this deadly disease, according to a new national analysis of trends and outcomes. Physician-scientists at University Hospitals Case Medical Center and Case Western Reserve University School of Medicine presented their findings and strategies to increase rates on March 13 at the Society of Surgical Oncology Cancer Symposium in Phoenix.

14 Mar 2014

Researchers find effective strategy to eliminate cancer stem-like cells

Combining nanodrug-based chemotherapy and cryoablation provides an effective strategy to eliminate cancer stem-like cells (CSCs) the root of cancer resistance and metastasis, which will help to improve the safety and efficacy of treating malignancies that are refractory to conventional therapies.

14 Mar 2014

AnaptysBio announces strategic immuno-oncology collaboration with TESARO

AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced a strategic immuno-oncology collaboration with TESARO, Inc., an oncology-focused biopharmaceutical company.

13 Mar 2014

Surefire Medical's new line of Surefire Guiding Catheters receive FDA clearance and CE Mark

Surefire Medical, Inc., developer of a new class of infusion systems designed to maximize direct-to-tumor drug delivery, announced today that the company has received 510(k) FDA clearance and the CE Mark for its enhanced line of Surefire Guiding Catheters used in radioembolization and chemoembolization procedures.

13 Mar 2014

Patient with advanced bladder cancer shows complete response to everolimus and pazopanib drugs

A patient with advanced bladder cancer experienced a complete response for 14 months to the drug combination everolimus and pazopanib in a phase I trial, and genomic profiling of his tumor revealed two alterations that may have caused this exceptional response, according to a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

13 Mar 2014

Two synergistic therapies allow solid tumors to act as their own cancer-fighting vaccine

Researchers in the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute eradicated solid tumors in laboratory mice using a novel combination of two targeted agents. These two synergistic therapies stimulate an immune response, ultimately allowing solid tumors to act as their own cancer-fighting vaccine.

13 Mar 2014

Duke-NUS researchers shed light on process that inhibits tumor development

A team of researchers from Duke-NUS Graduate Medical School have discovered a protein complex that disrupts the process known as dedifferentiation, known to promote tumor development.

13 Mar 2014

MUSC, Alliance Oncology announce strategic radiation therapy affiliation

The Medical University of South Carolina (MUSC), one of the nation's top academic health science centers, and Alliance Oncology, a division of Alliance HealthCare Services, Inc., announce a newly formed affiliation designed to strengthen and expand MUSC's Hollings Cancer Center as the radiation therapy market leader in Charleston, South Carolina.

12 Mar 2014

Rheumatoid arthritis and switching TNFis: an interview with Professor Paul Emery, University of Leeds

Tumor necrosis factor inhibitors (TNFis) are used to treat inflammatory conditions, such as RA. These agents work by blocking TNF, an important mediator of inflammation in RA, in order to help reduce inflammation and stop disease progression.

12 Mar 2014

Scientists study how cancer spreads through the body

Because of results seen in flat lab dishes, biologists have believed that cancers cells move through the body in a slow, aimless fashion, resembling an intoxicated person who cannot walk three steps in a straight line.

12 Mar 2014

Oncologists use mathematical model to develop treatment plans for cancer patients

Physics applies to everything. So when Vittorio Cristini, PhD, started researching cancer, he applied physics. The result he got was a set of mathematical equations that describe, for each person, how many of their tumor cells a cancer treatment could kill.

12 Mar 2014

MIT biologists discover how cancer cells make their escape

About 90 percent of cancer deaths are caused by tumors that have spread from their original locations. This process, known as metastasis, requires cancer cells to break loose from their neighbors and from the supportive scaffold that gives tissues their structure.

11 Mar 2014

CT scans predict effectiveness of chemotherapy for pancreatic cancer

Computed tomography (CT) scans routinely taken to guide the treatment of pancreatic cancer may provide an important secondary benefit. According to new research from The University of Texas MD Anderson Cancer Center, the scans also reflect how well chemotherapy will penetrate the tumor, predicting the effectiveness of treatment.

11 Mar 2014

Rexahn reports initial results from Supinoxin Phase I trial in patients with solid cancer tumors

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company announced today initial data for the Phase I dose-escalation clinical trial of SupinoxinTM (RX-5902) initiated in August 2013. This trial was designed to study safety and efficacy in patients with solid cancer tumors.

11 Mar 2014

Synta Pharmaceuticals' Hsp90 inhibitor ganetespib selected for study in I-SPY 2 TRIAL

Synta Pharmaceuticals Corp. and QuantumLeap Healthcare Collaborative today announced that Synta's lead drug candidate, the Hsp90 inhibitor ganetespib, has been selected for study in the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2).

11 Mar 2014

Tumor News and Research

Findings reveal potential drug targets for small cell lung cancer

Findings reveal that miR-34 genes are bona fide tumor suppressors

Longer looks: The 'making of Obamacare;' unlocking an autistic son's secrets; antibiotics and the obesity epidemic

Researcher discover new chemical class that attacks two key cancer cell building block targets

MD Anderson collaborates with MedImmune to develop therapies that unleash patients' immune systems to attack cancers

Physician-scientists present pancreatic cancer surgery findings at SSO Cancer Symposium

Researchers find effective strategy to eliminate cancer stem-like cells

AnaptysBio announces strategic immuno-oncology collaboration with TESARO

Surefire Medical's new line of Surefire Guiding Catheters receive FDA clearance and CE Mark

Patient with advanced bladder cancer shows complete response to everolimus and pazopanib drugs

Two synergistic therapies allow solid tumors to act as their own cancer-fighting vaccine

Duke-NUS researchers shed light on process that inhibits tumor development

MUSC, Alliance Oncology announce strategic radiation therapy affiliation

Rheumatoid arthritis and switching TNFis: an interview with Professor Paul Emery, University of Leeds

Scientists study how cancer spreads through the body

Oncologists use mathematical model to develop treatment plans for cancer patients

MIT biologists discover how cancer cells make their escape

CT scans predict effectiveness of chemotherapy for pancreatic cancer

Rexahn reports initial results from Supinoxin Phase I trial in patients with solid cancer tumors

Synta Pharmaceuticals' Hsp90 inhibitor ganetespib selected for study in I-SPY 2 TRIAL

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News